Timeline for palbociclib availability in the UK NHS.
ADVERSE EVENTS, METASTATIC BREAST CANCER
EU European Union, NICE National Institute for Health and Care Excellence, IPP Ibrance® Patient Pathway Program, SMC Scottish Medicines Consortium, HR hormone receptor, HER2 Human epidermal growth factor 2, LA locally advanced, MBC metastatic breast cancer.The objectives of the present study were to describe the patient characteristics, real-world treatment patterns, clinical outcomes and selected adverse events in the first group of patients treated with palbociclib as part of the IPP in routine clinical practice.